Joining the William Harvey Research Institute means that you’ll be taught by experts in their fields.
Sir Mark Caulfield is Professor of Clinical Pharmacology and an NHS consultant. His research has been independently rated amongst the top ten scientific discoveries in his field, and he has won numerous awards. He raised £25m toward the William Harvey Heart Centre which created a translational clinical research centre and was the academic leader that created the Barts Heart Centre bringing 3 hospitals together to create the UK’s largest heart centre. His main research focuses on cardiovascular genomics and cardiovascular clinical trials.
Mark was Chief Scientist for Genomics England until 31 July 2021, charged with delivery of the 100,000 Genomes Project on whole genome sequencing in rare disease, cancer and infection. He leads on all scientific activities for Genomics England including engagement with NHS scientific teams and the general public to promote, explain and enthuse about the project.
He has now taken on the new role of Chief Executive Officer at Barts Life Sciences, a research and innovation partnership between Queen Mary University of London and Barts Health NHS Trust, which is driving the development of a world-leading life sciences campus at Whitechapel focusing on digital health, genomics and clinical innovation.
Professor Deloukas is Professor of Cardiovascular Genomics, and Director of the William Harvey Research Institute. Panos has authored more than 400 publications during his career and been named in the top 0.1% of the world’s most influential researchers since the Highly Cited Researchers list was implemented in 2014.
Following his PhD, he joined the Sanger Centre where he led an effort to map 30,000 gene markers, GeneMap98. Panos was also an active member of the Human Genome Project coordinating the sequencing and analysis of chromosomes 10 and 20. He then joined the International HapMap project constructing SNP maps of the human genome. Since 2005 he has been studying the molecular basis of common disease and variable response to drugs in humans through large-scale genetic studies. At the William Harvey Research Institute, his research group investigates the molecular basis of complex traits in humans focusing on coronary heart disease (CHD) and related cardiometabolic traits.
Professor Druce is a Consultant Physician and Endocrinologist at Barts Health NHS Trust and Professor of Endocrine Medicine at the William Harvey Research Institute. Maralyn is the programme director for the MSc and postgraduate diplomas in Clinical Endocrinology, and Endocrinology and Diabetes. Her research interests include pathophysiology, diagnosis and treatment of neuroendocrine tumours, factors affecting the production of catecholamines and metanephrines, endocrine effects of cancer therapies, and gut hormones in the pathophysiology and treatment of obesity. She is also involved in industry-sponsored clinical trials of novel pharmacological therapies.
In addition, Professor Druce is a Fellow of the Royal College of Physicians, and holds a Senior Fellowship of the Higher Education Academy. Her research on endocrinology and teaching and learning in medical education has published extensively.
Professor Hobbs is the programme lead for the MRes Cardiac and Vascular Medicine and has gained worldwide recognition for his work with a number of Fellowships and sponsorship from the British Heart Foundation, British Lung Foundation, and Wellcome Trust among others. Within the Heart Centre at the William Harvey Research Institute, Adrian aims to develop and evaluate novel treatments of cardiovascular disease stemming from his research focused on ischaemic disorders (myocardial infarction, stroke), pulmonary hypertension and heart failure.
Professor Hobb’s research focuses on the physiological and pathological actions and interactions of a family of homologous enzymes, the guanylyl cyclases (GC) in relation to the cardiovascular system. These act as receptors for nitric oxide and natriuretic peptides and exert complementary cytoprotective, anti-atherosclerotic effects on the heart and vasculature. In accord, loss of these signaling pathways precipitates cardiovascular disease.
His research group adopts a multidisciplinary molecule-to-man approach including cell and molecular biology, biochemistry, in vitro and in vivo pharmacology, and clinical studies in healthy volunteers and patients, to investigate the significance of these enzymes in health and disease. The translational aspects of his work is highlighted by the ‘drug development’ programmes that are approaching or currently undergoing clinical evaluation.
Professor Atholl Johnston is Emeritus Professor of Clinical Pharmacology and Programme Director for MSc Clinical Drug Development, MRes/PGDip Clinical Research, and MSc/PGDip Healthcare Research Methods. He is a Fellow of the British Pharmacological Society, the Royal College of Pathologists, the Royal Society of Medicine, the Royal Statistical Society and an honorary member of the Faculty of Pharmaceutical Medicine.
Professor Johnston’s research interests are in drug use and abuse, drug quality, clinical trial design and statistical data analysis, modelling pharmacokinetics and pharmacodynamics, and in the optimal use of drugs with particular reference to immunosuppresive, cardiovascular, analgesic and anti-cancer drugs.
His research has assisted with the introduction of biosimilars to the NHS. He was the pharmacokinetic and statistical expert on the data safety monitoring board for the pivotal studies that led to the introduction of the first biosimilar to infliximab, Remsima®. He has also played an important role in the breaking of subsidiary patents obstructing the introduction of biosimilar products. One instance has resulted in a saving of £150million per year to the NHS.
Professor Johnston was appointed to expert panels convened by the Department for Transport (DfT) and the Home Office to look at the evidence and to advise on which drugs to include in legislation and at what blood concentration the limits should be set with regards to drug-driving. The introduction of the offence has resulted in over 40,000 additional convictions for drug-driving.
Professor Johnston has held, and holds, several national leadership roles in Forensic Toxicology. In addition, he is Science Director of Analytical Services International, one of the very few UK laboratories accredited to ISO 17025 by the UK Accreditation Service (UKAS) for the analysis of all seventeen drugs in blood from motorists suspected of committing Section 5A Road Traffic Act offences.
Professor Márta Korobonits, is Professor of Endocrinology and Metabolism, and Deputy Director at the William Harvey Research Institute and Honorary Consultant at Barts Health NHS Trust. Her research interests include endocrine tumorigenesis, particularly the genetic origin of pituitary adenomas and other endocrine tumour syndromes.
Over the last decade, her major research focus involves the clinical and scientific aspects of familial isolated pituitary adenomas. In addition to her research, she looks after patients with endocrine diseases at St. Bartholomew’s Hospital. She has been a recipient of awards from the British, Irish, Australian and the US Endocrine Societies and the Royal College of Physicians. Márta divides her time between clinical patient care, clinical and laboratory based research, as well as teaching at undergraduate and postgraduate level including supervision of MSc and PhD students.
Professor Lemos is a chartered forensic scientist who started his career in the field for analytical and forensic toxicology researching drug analysis in fingernails and other biological specimens. He has worked in London, UK supervising the provision of toxicology services to HM Coroners, Home Office Pathologists and Police Forces and in the USA, where has was Chief Forensic Toxicologist and Director of the Forensic Laboratory Division at the Office of the Chief Medical Examiner of the City and County of San Francisco in California.
Professor Lemos is a Member of the Chartered Society of Forensic Scientists, Fellow of the American Board of Forensic Toxicologists, Fellow of the Royal Society of Chemistry, and Fellow of the American Academy of Forensic Sciences.
He consults and testifies in criminal and civil cases around the world, and has testified in over 325 cases and offered opinions to assist the courts in response to subpoenas issued by both prosecutors as well as defence attorneys.
Nikolas has co-authored over 85 peer-reviewed papers, abstracts, and book chapters. His research interests include Forensic Toxicology; Analytical and Forensic Laboratory Accreditation; and Epidemiology of Drugs and Poisons.
Dylan Morrissey is a Consultant Physiotherapist and Professor of Sports and Musculoskeletal Physiotherapy. He leads the interdisciplinary Sports and Exercise Medicine (SEM) team at Queen Mary.
Professor Morrissey is a fellow of the Higher Education Academy and provides academic leadership to the Sports and Exercise Medicine educational programmes. Dylan runs the Human Performance Laboratory and has gained more than £7million in research funding, with a third as lead applicant, and has authored approximately 90 peer-reviewed full papers. His main research interests are tendinopathy, evidence translation and the link between movement and pathology. He has an increasing focus on data management and artificial intelligence.
His sporting passion is paralympic sport, and he was a headquarters physiotherapist for London 2012 and Rio 2016.
Professor Rupert Pearse is the NIHR Professor of Intensive Care Medicine and his research is focused on improving the care pathway for patients before, during and after major surgery. This includes the study of risk factors for poor health, interventions during surgery which may improve patient outcomes, through to better ways to make decisions about surgical treatments with patients. This increasingly includes care of patients who need surgical treatments in low and middle-income countries as well as high-income countries. His clinical duties are based on the busy Adult Critical Care Unit at The Royal London Hospital where he oversees the care of patients with critical illnesses of various causes.
During the COVID-19 pandemic, Professor Pearse was in the media warning that the impact on the NHS would be ‘catastrophic’ if people failed to take lockdown in the UK seriously.
Professor Vanezis is Professor Emeritus of Forensic Medical Sciences, and Director of Cameron Forensic Medical Sciences. Peter’s research interests include facial identification, forensic pathology, especially in relation timing of injuries and projects involving the next of kin of deceased persons reported to the coroner. He has successfully received over one million pounds in research grants. He teaches regularly to both undergraduates and postgraduate students and co-ordinates a number of postgraduate courses. He has also published widely in forensic medicine in peer reviewed journals, has edited two books and contributed to a number of other textbooks.
Professor Vanezis has conducted in excess of 2,000 suspicious death autopsies, of which approximately 1,500 were homicides. He has also carried out autopsies abroad, including on behalf of the United Nations International Criminal Tribunal in the former Yugoslavia and in Rwanda. In addition he has assisted with identification of deceased from mass graves in Chile, and Sri Lanka. He has been the supervising pathologist in a number of multiple death incidents (major disasters) and involved in high-profile cases including being invited to investigate the circumstances surrounding the death of Princess Diana, advising the Russian authorities on the identification of the Romanovs, and involved in the study of the Tyrolean Iceman (Ötzi).
Dr Zolfaghari is the programme director for the MSc Critical Care and a consultant in Critical Care Medicine and Anaesthesia at The Royal London Hospital, with special interest in trauma, respiratory failure and support, hepatobiliary surgery and microbiology. He is also a Fellow of the Higher Education Academy.
Parjam’s research interests include muscle loss and metabolism in critical illness, and sepsis and hospital-acquired infections.
Dr Zolfaghari’s work as the lead on the Critical Care MSc was recognised at the Queen Mary Education Excellence Awards. The awards recognise excellence in teaching and learner support at institutional level.